Cargando…

Dimeric Lectin Chimeras as Novel Candidates for Gb3-Mediated Transcytotic Drug Delivery through Cellular Barriers

Receptor-mediated transcytosis is an elegant and promising strategy for drug delivery across biological barriers. Here, we describe a novel ligand–receptor pair based on a dimeric, engineered derivative of the Pseudomonas aeruginosa lectin LecA, here termed Di-LecA, and the host cell glycosphingolip...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Maokai, Antonova, Maria, Salavei, Pavel, Illek, Katharina, Meléndez, Ana Valeria, Omidvar, Ramin, Thuenauer, Roland, Makshakova, Olga, Römer, Winfried
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9864468/
https://www.ncbi.nlm.nih.gov/pubmed/36678854
http://dx.doi.org/10.3390/pharmaceutics15010225
_version_ 1784875592312684544
author Xu, Maokai
Antonova, Maria
Salavei, Pavel
Illek, Katharina
Meléndez, Ana Valeria
Omidvar, Ramin
Thuenauer, Roland
Makshakova, Olga
Römer, Winfried
author_facet Xu, Maokai
Antonova, Maria
Salavei, Pavel
Illek, Katharina
Meléndez, Ana Valeria
Omidvar, Ramin
Thuenauer, Roland
Makshakova, Olga
Römer, Winfried
author_sort Xu, Maokai
collection PubMed
description Receptor-mediated transcytosis is an elegant and promising strategy for drug delivery across biological barriers. Here, we describe a novel ligand–receptor pair based on a dimeric, engineered derivative of the Pseudomonas aeruginosa lectin LecA, here termed Di-LecA, and the host cell glycosphingolipid Gb3. We characterized the trafficking kinetics and transcytosis efficiencies in polarized Gb3-positive and -negative MDCK cells using mainly immunofluorescence in combination with confocal microscopy. To evaluate the delivery capacity of dimeric LecA chimeras, EGFP was chosen as a fluorescent model protein representing macromolecules, such as antibody fragments, and fused to either the N- or C-terminus of monomeric LecA using recombinant DNA technology. Both LecA/EGFP fusion proteins crossed cellular monolayers in vitro. Of note, the conjugate with EGFP at the N-terminus of LecA (EGFP-LecA) showed a higher release rate than the conjugate with EGFP at the C-terminus (LecA-EGFP). Based on molecular dynamics simulations and cross-linking studies of giant unilamellar vesicles, we speculate that EGFP-LecA tends to be a dimer while LecA-EGFP forms a tetramer. Overall, we confidently propose the dimeric LecA chimeras as transcytotic drug delivery tools through Gb3-positive cellular barriers for future in vivo tests.
format Online
Article
Text
id pubmed-9864468
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98644682023-01-22 Dimeric Lectin Chimeras as Novel Candidates for Gb3-Mediated Transcytotic Drug Delivery through Cellular Barriers Xu, Maokai Antonova, Maria Salavei, Pavel Illek, Katharina Meléndez, Ana Valeria Omidvar, Ramin Thuenauer, Roland Makshakova, Olga Römer, Winfried Pharmaceutics Article Receptor-mediated transcytosis is an elegant and promising strategy for drug delivery across biological barriers. Here, we describe a novel ligand–receptor pair based on a dimeric, engineered derivative of the Pseudomonas aeruginosa lectin LecA, here termed Di-LecA, and the host cell glycosphingolipid Gb3. We characterized the trafficking kinetics and transcytosis efficiencies in polarized Gb3-positive and -negative MDCK cells using mainly immunofluorescence in combination with confocal microscopy. To evaluate the delivery capacity of dimeric LecA chimeras, EGFP was chosen as a fluorescent model protein representing macromolecules, such as antibody fragments, and fused to either the N- or C-terminus of monomeric LecA using recombinant DNA technology. Both LecA/EGFP fusion proteins crossed cellular monolayers in vitro. Of note, the conjugate with EGFP at the N-terminus of LecA (EGFP-LecA) showed a higher release rate than the conjugate with EGFP at the C-terminus (LecA-EGFP). Based on molecular dynamics simulations and cross-linking studies of giant unilamellar vesicles, we speculate that EGFP-LecA tends to be a dimer while LecA-EGFP forms a tetramer. Overall, we confidently propose the dimeric LecA chimeras as transcytotic drug delivery tools through Gb3-positive cellular barriers for future in vivo tests. MDPI 2023-01-09 /pmc/articles/PMC9864468/ /pubmed/36678854 http://dx.doi.org/10.3390/pharmaceutics15010225 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Xu, Maokai
Antonova, Maria
Salavei, Pavel
Illek, Katharina
Meléndez, Ana Valeria
Omidvar, Ramin
Thuenauer, Roland
Makshakova, Olga
Römer, Winfried
Dimeric Lectin Chimeras as Novel Candidates for Gb3-Mediated Transcytotic Drug Delivery through Cellular Barriers
title Dimeric Lectin Chimeras as Novel Candidates for Gb3-Mediated Transcytotic Drug Delivery through Cellular Barriers
title_full Dimeric Lectin Chimeras as Novel Candidates for Gb3-Mediated Transcytotic Drug Delivery through Cellular Barriers
title_fullStr Dimeric Lectin Chimeras as Novel Candidates for Gb3-Mediated Transcytotic Drug Delivery through Cellular Barriers
title_full_unstemmed Dimeric Lectin Chimeras as Novel Candidates for Gb3-Mediated Transcytotic Drug Delivery through Cellular Barriers
title_short Dimeric Lectin Chimeras as Novel Candidates for Gb3-Mediated Transcytotic Drug Delivery through Cellular Barriers
title_sort dimeric lectin chimeras as novel candidates for gb3-mediated transcytotic drug delivery through cellular barriers
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9864468/
https://www.ncbi.nlm.nih.gov/pubmed/36678854
http://dx.doi.org/10.3390/pharmaceutics15010225
work_keys_str_mv AT xumaokai dimericlectinchimerasasnovelcandidatesforgb3mediatedtranscytoticdrugdeliverythroughcellularbarriers
AT antonovamaria dimericlectinchimerasasnovelcandidatesforgb3mediatedtranscytoticdrugdeliverythroughcellularbarriers
AT salaveipavel dimericlectinchimerasasnovelcandidatesforgb3mediatedtranscytoticdrugdeliverythroughcellularbarriers
AT illekkatharina dimericlectinchimerasasnovelcandidatesforgb3mediatedtranscytoticdrugdeliverythroughcellularbarriers
AT melendezanavaleria dimericlectinchimerasasnovelcandidatesforgb3mediatedtranscytoticdrugdeliverythroughcellularbarriers
AT omidvarramin dimericlectinchimerasasnovelcandidatesforgb3mediatedtranscytoticdrugdeliverythroughcellularbarriers
AT thuenauerroland dimericlectinchimerasasnovelcandidatesforgb3mediatedtranscytoticdrugdeliverythroughcellularbarriers
AT makshakovaolga dimericlectinchimerasasnovelcandidatesforgb3mediatedtranscytoticdrugdeliverythroughcellularbarriers
AT romerwinfried dimericlectinchimerasasnovelcandidatesforgb3mediatedtranscytoticdrugdeliverythroughcellularbarriers